(Reuters) – British drugmaker Indivior on Thursday projected a 17% decline in 2025 net revenue at the midpoint of its forecast range, partly hurt by sluggish sales of its film-form medication-assisted therapy for opiate addiction.
The company expects 2025 net revenue between $955 million and $1.03 billion. It reported a 16% rise in adjusted operating profit to $312 million for the year ended December 31, 2024.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Subhranshu Sahu)
Comments